AU2003248122A8 - Sodium channel inhibitor - Google Patents

Sodium channel inhibitor

Info

Publication number
AU2003248122A8
AU2003248122A8 AU2003248122A AU2003248122A AU2003248122A8 AU 2003248122 A8 AU2003248122 A8 AU 2003248122A8 AU 2003248122 A AU2003248122 A AU 2003248122A AU 2003248122 A AU2003248122 A AU 2003248122A AU 2003248122 A8 AU2003248122 A8 AU 2003248122A8
Authority
AU
Australia
Prior art keywords
sodium channel
channel inhibitor
inhibitor
sodium
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003248122A
Other versions
AU2003248122A1 (en
Inventor
Toshihiro Watanabe
Yukinori Nagakura
Hiroshi Tomiyama
Motoharu Sonegawa
Kazuo Tokuzaki
Yoshinori Iwai
Kazumi Kikuchi
Makoto Oku
Takeshi Hondo
Tetsuya Kimizuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Kotobuki Seiyaku Co Ltd
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd, Yamanouchi Pharmaceutical Co Ltd filed Critical Kotobuki Seiyaku Co Ltd
Publication of AU2003248122A8 publication Critical patent/AU2003248122A8/en
Publication of AU2003248122A1 publication Critical patent/AU2003248122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003248122A 2002-07-25 2003-07-25 Sodium channel inhibitor Abandoned AU2003248122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002216187 2002-07-25
JP2002-216187 2002-07-25
PCT/JP2003/009474 WO2004011430A1 (en) 2002-07-25 2003-07-25 Sodium channel inhibitor

Publications (2)

Publication Number Publication Date
AU2003248122A8 true AU2003248122A8 (en) 2004-02-16
AU2003248122A1 AU2003248122A1 (en) 2004-02-16

Family

ID=31184572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248122A Abandoned AU2003248122A1 (en) 2002-07-25 2003-07-25 Sodium channel inhibitor

Country Status (3)

Country Link
JP (1) JPWO2004011430A1 (en)
AU (1) AU2003248122A1 (en)
WO (1) WO2004011430A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408136A (en) 2003-03-07 2006-03-01 Astellas Pharma Inc nitrogen-containing heterocyclic derivatives having 2,6-disubstituted styryl
RU2006117631A (en) * 2003-10-24 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) CCR3 RECEPTOR ANTAGONISTS
CA2578604A1 (en) * 2004-09-01 2006-03-09 Astellas Pharma Inc. Piperidine derivative or pharmaceutically acceptable salt thereof
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051095A1 (en) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND ITS USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0514615D0 (en) 2005-07-15 2005-08-24 Novartis Ag Organic compounds
DOP2006000210A (en) * 2005-10-04 2007-06-15 Aventis Pharma Inc AMIDA PYRIMIDINE COMPOUNDS AS PGDS INHIBITORS
AU2006327243A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
RU2364597C1 (en) 2007-12-14 2009-08-20 Андрей Александрович Иващенко HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM
JP5592388B2 (en) * 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション Technical field of P2X3 receptor antagonist for the treatment of pain
WO2011016234A1 (en) * 2009-08-04 2011-02-10 Raqualia Pharma Inc. Picolinamide derivatives as ttx-s blockers
US8361998B2 (en) 2010-11-30 2013-01-29 Astrazeneca Ab Compounds and their use as IKACh blockers
JP6117708B2 (en) * 2011-03-18 2017-04-19 ジェンザイム・コーポレーション Glucosylceramide synthase inhibitor
MA37975B2 (en) 2012-09-11 2021-03-31 Genzyme Corp Glucosylceramide synthase inhibitors
KR20200094734A (en) 2017-09-22 2020-08-07 주빌런트 에피파드 엘엘씨 Heterocyclic compounds as PAD inhibitors
DK3697785T3 (en) 2017-10-18 2023-04-03 Jubilant Epipad LLC IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CA3083374A1 (en) 2017-11-24 2019-05-31 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
UA127747C2 (en) 2018-10-23 2023-12-20 Басф Се Tricyclic pesticidal compounds
BR112023000798A2 (en) 2020-07-24 2023-02-07 Genzyme Corp PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUTAT

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB925429A (en) * 1960-04-01 1963-05-08 Irwin Neisler & Co Indole derivatives
DE3643666A1 (en) * 1986-12-20 1988-06-30 Thomae Gmbh Dr K NEW CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3735895A1 (en) * 1987-10-23 1989-05-03 Thomae Gmbh Dr K CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING THESE COMPOUNDS
DE3819444A1 (en) * 1988-06-08 1989-12-14 Thomae Gmbh Dr K NEW CONDENSED DIAZEPINONE, PROCESS FOR THEIR MANUFACTURE AND MEDICAMENTS CONTAINING THESE COMPOUNDS
FR2668149B1 (en) * 1990-10-18 1994-09-23 Synthelabo 1- (3,4-DIHYDRO-2-OXO-1H-QUINOLEIN-6-YL) -2- [4- (2-PHENYL-ETHYL) PIPERIDIN-1-YL] ETHANOL, ITS PREPARATION AND THERAPEUTIC APPLICATION .
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
EP0910565A1 (en) * 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
CA2232147A1 (en) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives
DE19756235A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
FR2803298A1 (en) * 1999-12-30 2001-07-06 Adir NOVEL LINEAR OR CYCLIC UREAS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP4282048B2 (en) * 2000-01-20 2009-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Novel piperidine compounds and pharmaceuticals thereof

Also Published As

Publication number Publication date
WO2004011430A1 (en) 2004-02-05
JPWO2004011430A1 (en) 2005-11-24
AU2003248122A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
AU2003248122A8 (en) Sodium channel inhibitor
EG25482A (en) Inhibitors
EP1532133A4 (en) Nf-:b inhibitors
EP1501509A4 (en) Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
HRP20050162A2 (en) ?-lactamase inhibitor prodrug
PL397821A1 (en) 1-acetyl-6-fluoro-2-indolinone compound
GB0204241D0 (en) Compound
EP1531857A4 (en) Metalloproteinase inhibitors
AU2003256323A8 (en) Sos1 inhibitors
GB0225750D0 (en) Wiffs away
EP1501790A4 (en) Novel sodium channel blockers
GB2374269B (en) Lawn-edging strip
EP1609479A4 (en) Tumorigenesis inhibitor
GB0224830D0 (en) Compound
GB2385877B (en) Threshold
GB0213027D0 (en) Compound
GB0216212D0 (en) Sodium channel inhibitors
GB0116730D0 (en) Sodium channel inhibitors
IL165935A (en) Vasopeptidase inhibitors
GB0217330D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors
GB0224102D0 (en) Inhibitors
GB0206031D0 (en) Inhibitors
GB0207488D0 (en) Inhibitors
GB0207491D0 (en) Inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 12, PAGE(S) 3443 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME YAMANOUCHI PHARMACEUTICAL CO., LTD., APPLICATION NO. 2003248122, UNDER INID (71) CORRECT THE NAME TO READ KOTOBUKI PHARMACEUTICAL CO., LTD.; YAMANOUCHI PHARMACEUTICAL CO., LTD.